Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression
Standard
Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. / Bednarz-Knoll, Natalia; Nastały, Paulina; Żaczek, Anna; Stoupiec, Małgorzata ; Riethdorf, Sabine; Wikman-Kocher, Harriet; Müller, Volkmar; Skokowski, Jarosław; Szade, Jolanta; Sejda, Aleksandra; Wełnicka-Jaśkiewicz, Marzena; Pantel, Klaus.
in: ONCOTARGET, Jahrgang 6, Nr. 29, 29.09.2015, S. 26789-803.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression
AU - Bednarz-Knoll, Natalia
AU - Nastały, Paulina
AU - Żaczek, Anna
AU - Stoupiec, Małgorzata
AU - Riethdorf, Sabine
AU - Wikman-Kocher, Harriet
AU - Müller, Volkmar
AU - Skokowski, Jarosław
AU - Szade, Jolanta
AU - Sejda, Aleksandra
AU - Wełnicka-Jaśkiewicz, Marzena
AU - Pantel, Klaus
PY - 2015/9/29
Y1 - 2015/9/29
N2 - Interactions between cancer cells and microenvironment are emerging issue in tumor progression. Aldehyde dehydrogenase 1 (ALDH1) is a recognized cancer stem cell marker but little is known about its role in intratumoral stroma. Therefore, we focused on ALDH1 expression in tumor-associated stroma of breast carcinomas (BrCa). Stromal and tumoral ALDH1 expression was evaluated immunohistochemically in BrCa and their lymph node metastases (LNMs), and related to clinico-pathological characteristics, patients' outcome, presence of CD68, HLADR, retinoic acid (RA) in stroma, and selected proteins in tumor cells. ALDH1(+) stromal cells were detected in 53% of 374 BrCa and 61% of 102 LNMs. ALDH1(+) stroma in primary tumor correlated to longer disease-free (p = 0.030), metastasis-free (p = 0.024), and overall survival (p = 0.043) having an independent prognostic impact on DFS (multivariate analysis, p = 0.047). It was associated with concomitant presence of HLA-DR(+) stromal cells and RA in tumor cells (both p < 0.001), and inversely associated with vimentin expression in tumor cells (p = 0.036). ALDH1(+) stroma in LNMs correlated inversely to presence of disseminated tumor cells in patients' bone marrow (p = 0.014) and was independent prognosticator of shorter DFS and MFS (multivariate analysis, p = 0.004 and p = 0.002, respectively). In conclusion, ALDH1 expression in tumor-associated stromal cells indicates reduced BrCa progression, possibly via RA secretion.
AB - Interactions between cancer cells and microenvironment are emerging issue in tumor progression. Aldehyde dehydrogenase 1 (ALDH1) is a recognized cancer stem cell marker but little is known about its role in intratumoral stroma. Therefore, we focused on ALDH1 expression in tumor-associated stroma of breast carcinomas (BrCa). Stromal and tumoral ALDH1 expression was evaluated immunohistochemically in BrCa and their lymph node metastases (LNMs), and related to clinico-pathological characteristics, patients' outcome, presence of CD68, HLADR, retinoic acid (RA) in stroma, and selected proteins in tumor cells. ALDH1(+) stromal cells were detected in 53% of 374 BrCa and 61% of 102 LNMs. ALDH1(+) stroma in primary tumor correlated to longer disease-free (p = 0.030), metastasis-free (p = 0.024), and overall survival (p = 0.043) having an independent prognostic impact on DFS (multivariate analysis, p = 0.047). It was associated with concomitant presence of HLA-DR(+) stromal cells and RA in tumor cells (both p < 0.001), and inversely associated with vimentin expression in tumor cells (p = 0.036). ALDH1(+) stroma in LNMs correlated inversely to presence of disseminated tumor cells in patients' bone marrow (p = 0.014) and was independent prognosticator of shorter DFS and MFS (multivariate analysis, p = 0.004 and p = 0.002, respectively). In conclusion, ALDH1 expression in tumor-associated stromal cells indicates reduced BrCa progression, possibly via RA secretion.
U2 - 10.18632/oncotarget.4628
DO - 10.18632/oncotarget.4628
M3 - SCORING: Journal article
C2 - 26305673
VL - 6
SP - 26789
EP - 26803
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 29
ER -